FDA named Executive of former Pharmaceutical Company to oversee American drug program

FDA named Executive of former Pharmaceutical Company to oversee American drug program

Washington (AP) – Food and Drug Administration on Monday named a long -term pharmaceutical executive to run the agency’s drug program, the latest in a string of change in leadership in the agency.

FDA Commissioner Marti Makeri Announced that a cancer and pediatrician Dr. George Tidmarsh will direct the drug evaluation and research to the center of the agency, which controls the safety and effectiveness of all American drugs.

His appointment was the acting director of the center, Dr. Jacqueline Korigan-Kure comes a month after declaring her retirement.

As the agency’s top drug regulator, will be charged through many Makary commitment And his boss, Health Secretary Robert F. Kennedy Junior, including review Abortion pill mifiprystone’s safetyThe FDA is also examining some of the other long-standing drugs, including antidepressant and hormone-ripeness drugs for menopause.

Tidmarsh established and led several pharmaceutical companies, including horizons pharmaceuticals, who are an anti -inflammatory drug manufacturer for arthritis. He has also worked as an assistant professor at Stanford University.

The FDA’s drug center is the largest unit of the agency, with around 6,000 employees responsible for reviewing the safety and effectiveness of new drugs and monitoring the use and marketing of chronic drugs.

Around 2,000 FDA employees have been placed as part of Widescale Kennedy cuts the care of the federal health workforceMore than 1,000 others have taken purchases or initial retirement, while many others are allegedly searching for new jobs. The departure threatens basic FDA operations, including timely review of new drugs.

The FDA’s drug center was not a permanent director since January, when Dr. Patricia Kavazoni stepped into a few days before President Donald Trump took over.

ALSO READ  What do you know about Bangladesh Air Force Jet accident in a Dhaka school

Almost all senior leadership positions of the FDA have been converted into recent months, either retirement, resignation or administration officials have been placed on administrative leave by the officials of the administration.

Directors of the FDA Center usually hold their positions for years or decades, many serve in administration, whether Republican or Democrats.

In May, Makari gave Dr. Vinay Prasad named, which is a prominent Critics of FDA’s covid responseTo run the agency’s vaccine center. He was also nominated as the Chief Medical Officer of the FDA. Prasad, his predecessor, long -time vaccine head Dr. Dr. Peter joined the agency after Marx, Was forced in march,

The head of the FDA tobacco center was also forced to step down In April. A permanent replacement has not been named yet.

,

The Associated Press Health and Science Department receives support from the Department of Science Education and Robert Wood Johnson Foundation of Howard Hughes Medical Institute. AP is completely responsible for all materials.

Matthew Peron, Associated Press

Join WhatsApp

Join Now